720
Views
9
CrossRef citations to date
0
Altmetric
Cardiovascular

Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter?

Pages 1845-1847 | Accepted 18 Aug 2015, Published online: 21 Sep 2015
 

Abstract

Once daily dosing schedule is associated with increased adherence to and persistence with cardiovascular therapies. Such feature has been claimed responsible for the significantly lower (both temporary and permanent) discontinuation of oral anticoagulation with rivaroxaban (which is given once daily) compared to dabigatran (which is given twice daily) in a large, real-world dataset of patients with atrial fibrillation (AF) in the United States. While a cause-effect relationship between dosing schedule and adherence and persistence could not be established, the above finding supports nonetheless the preferential selection of the non vitamin-K-antagonists oral anticoagulant (NOAC) with the easiest and most convenient regimen. Given however, the differences in efficacy and safety observed with the various NOACs compared to warfarin in the phase III clinical trials in non-valvular AF, careful individualization of treatment should be pursued, being dosing schedule only one of the variables to be taken into account. Maximal effort instead, should be put in implementing measures to enhance patient's adherence to and persistence with treatment.

Transparency

Declaration of funding

This editorial was not funded.

Declaration of financial/other relationships

A.R. has disclosed that he has received honoraria from and/or performed consulting for: Bayer, Boehringer Ingelheim, Daiichi Sankyo, Pfizer-Bristol Myers Squibb, Astra Zeneca.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.